Gyre Therapeutics (GYRE) Competitors $7.90 +0.07 (+0.89%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.86 -0.04 (-0.57%) As of 09/15/2025 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. MOR, HCM, BHC, OGN, KNSA, GMTX, CGON, ALVO, CPRX, and TARSShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include MorphoSys (MOR), HUTCHMED (HCM), Bausch Health Cos (BHC), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors MorphoSys HUTCHMED Bausch Health Cos Organon & Co. Kiniksa Pharmaceuticals International Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals MorphoSys (NASDAQ:MOR) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Do insiders & institutionals hold more shares of MOR or GYRE? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, MOR or GYRE? MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Do analysts prefer MOR or GYRE? Gyre Therapeutics has a consensus price target of $18.00, indicating a potential upside of 127.85%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MOR or GYRE? In the previous week, Gyre Therapeutics had 15 more articles in the media than MorphoSys. MarketBeat recorded 15 mentions for Gyre Therapeutics and 0 mentions for MorphoSys. Gyre Therapeutics' average media sentiment score of 1.54 beat MorphoSys' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Gyre Therapeutics Very Positive Which has stronger valuation and earnings, MOR or GYRE? Gyre Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Gyre Therapeutics$105.76M7.19$12.09M$0.01790.00 Is MOR or GYRE more profitable? Gyre Therapeutics has a net margin of 4.08% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of 7.67% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Gyre Therapeutics 4.08%7.67%6.19% SummaryGyre Therapeutics beats MorphoSys on 14 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$754.13M$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio790.7921.2475.0826.39Price / Sales7.19420.70508.41175.01Price / Cash39.6544.4425.8129.91Price / Book7.529.6413.596.28Net Income$12.09M-$53.20M$3.29B$270.38M7 Day Performance3.00%0.07%0.07%1.89%1 Month Performance-2.95%4.27%4.57%6.01%1 Year Performance-43.81%9.62%76.79%25.26% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics1.6725 of 5 stars$7.90+0.9%$18.00+127.8%-41.5%$754.13M$105.76M790.7940Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED2.6473 of 5 stars$16.11+0.9%$28.00+73.8%+1.4%$2.79B$630.20M0.001,811BHCBausch Health Cos4.5885 of 5 stars$7.33-0.3%$9.00+22.9%+13.4%$2.72B$9.63B28.1720,700OGNOrganon & Co.4.5149 of 5 stars$10.48+0.9%$17.33+65.5%-49.3%$2.70B$6.40B3.894,000Positive NewsKNSAKiniksa Pharmaceuticals International2.2198 of 5 stars$36.57+2.4%$41.17+12.6%+44.7%$2.65B$423.24M914.48220Short Interest ↑GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+25.2%$2.63BN/A-60.7630CGONCG Oncology2.4106 of 5 stars$33.69+1.9%$53.91+60.0%-0.6%$2.52B$1.14M-19.0361Analyst ForecastInsider TradeGap UpHigh Trading VolumeALVOAlvotech3.7617 of 5 stars$8.16-2.0%$14.00+71.6%-24.9%$2.51B$491.98M35.481,032Short Interest ↓CPRXCatalyst Pharmaceuticals4.953 of 5 stars$20.08-1.0%$33.20+65.3%-2.3%$2.48B$491.73M12.1780Positive NewsAnalyst DowngradeTARSTarsus Pharmaceuticals2.5144 of 5 stars$56.89-1.3%$66.67+17.2%+49.1%$2.43B$182.95M-24.4250Positive News Related Companies and Tools Related Companies MorphoSys Competitors HUTCHMED Competitors Bausch Health Cos Competitors Organon & Co. Competitors Kiniksa Pharmaceuticals International Competitors Gemini Therapeutics Competitors CG Oncology Competitors Alvotech Competitors Catalyst Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
